Nonprofit Pharma Targets Making Naloxone Available OTC, Trimming Price
This article was originally published in The Pink Sheet
Executive Summary
Nonprofit Harm Reduction Therapeutics targets an OTC switch of naloxone, an opioid antagonist used to reverse an opioid overdose. It aims to make the product available at low cost in 110,000 retail locations nationwide.
You may also be interested in...
US FDA Has Model Drug Facts Labels For OTC Naloxone, Needs Switch Proposals
Development of the model DFLs was a first for agency. The project was "part of our broader commitment to addressing the opioid crisis" and should help sponsors with potential naloxone OTC switch NDAs, says Commissioner Scott Gottlieb.
FDA Has Model Drug Facts Labels For OTC Naloxone, Wants Switch Proposals
Development of the model DFLs was a first for agency, reflecting alarm over public health crisis of overdoses from opioid abuse, which reached nearly 48,000 in 2017. The project was "part of our broader commitment to addressing the opioid crisis" and should help sponsors with potential naloxone OTC switch NDAs, says Commissioner Scott Gottlieb.
Declaring Opioid Emergency, Trump Touts FDA Actions, NIH-Industry Partnerships
Proclaiming the opioid epidemic a public health emergency, President points to FDA's prescriber training requirements and withdrawal of Opana ER; Sen. Leahy decries lack of additional funding.